Cold Pain Therapy Market Report 2025

The cold pain therapy market size has grown strongly in recent years. It will grow from $1.77 billion in 2024 to $1.89 billion in 2025 at a compound annual growth rate (CAGR) of 7.2%. The growth in the historic period can be attributed to rise in sports injuries, chronic pain management, post-surgery recovery, orthopedic applications, fitness and rehabilitation.

The cold pain therapy market size is expected to see strong growth in the next few years. It will grow to $2.53 billion in 2029 at a compound annual growth rate (CAGR) of 7.5%. The growth in the forecast period can be attributed to professional endorsements, innovative marketing strategies, digital health adoption, supportive regulatory environment, geriatric population demand, rise in orthopedic conditions. Major trends in the forecast period include increased sports and fitness focus, shift towards non-pharmacological methods, at-home treatment preference.

The growth of the cold pain therapy market is significantly influenced by the increased importance of gym activities. The rise in gym participation is driven by various health benefits, including enhanced brain health, weight management, reduced disease risk, strengthened bones and muscles, and improved daily functionality. Cold pain therapy products play a crucial role in alleviating pain associated with musculoskeletal injuries commonly incurred during gym activities. For example, in March 2022, data from the Australia Bureau of Statistics revealed that 73.4% of Australian adults aged 18 to 64 engaged in at least 150 minutes of physical activity regularly, indicating a higher potential for muscle and tendon injuries. Consequently, the growing emphasis on gym activities is expected to propel the cold pain therapy market.

The escalating number of road accidents is a significant factor contributing to the growth of the cold pain therapy market. Road accidents, involving various modes of transportation such as cars, motorcycles, bicycles, and pedestrians, lead to injuries that necessitate pain management solutions. Cold pain therapy products offer a non-invasive and accessible approach to relieve pain and support recovery following road accidents. Notably, according to the French Road Safety Observatory's 2023 update, mainland France witnessed 53.5 thousand injury traffic accidents, resulting in 67 thousand injured individuals last year. This surge in road accidents globally enhances the market potential for cold pain therapy products, driving market growth.

Technological advancements emerge as a prominent trend in the cold pain therapy market, with major companies striving to introduce innovative technologies to gain a competitive advantage. In April 2022, Jenburkt Wellness, an India-based company in the cold pain therapy sector, unveiled Zixa Strong - a fast-acting pain relief range. This innovation incorporates oil-in-water flash micelle technology, employing ultra-rapid mixing techniques to enhance the therapeutic efficacy of oil-based formulations. Technological advancements in product offerings contribute to the attractiveness and competitiveness of companies in the cold pain therapy market.

Major companies are strategically forming partnerships and collaborations with start-ups and mid-sized firms in the cold pain therapy market to expand their product and service offerings. These strategic alliances enable companies to enhance their existing product portfolios and increase their geographical reach. For example, in August 2023, Breg, a US-based company specializing in orthopedic bracing and billing services, announced a new international partnership with Amos Gazit Ltd., an Israel-based provider of products and services for the safety and medicine industries. This collaboration is designed to strengthen Breg's presence in the Israeli market by supplying high-quality orthopedic bracing and cold therapy products to healthcare providers and patients. This partnership aligns with Breg's strategy to improve its distribution capabilities and enhance the accessibility of orthopedic solutions, which frequently incorporate cold therapy techniques to boost pain management effectiveness.

In October 2022, Havencrest Capital Management, a US-based healthcare private equity firm, successfully acquired ThermoTek Inc. in a transaction whose financial details remain undisclosed. The acquisition aligns with Havencrest's strategic objective of expanding ThermoTek's product portfolio, utilizing the firm's extensive network of operating partners and senior advisors. ThermoTek Inc., based in the United States, specializes in the manufacturing of temperature management devices.

Major companies operating in the cold pain therapy market are Unexo Lifesciences Pvt. Ltd., Össur Corporate, Hisamitsu Pharmaceutical Co. Inc., Johnson & Johnson, Pfizer Inc., Sanofi S.A., Rohto Pharmaceutical Co. Ltd., 3M Company, Cardinal Health Inc., Compass Health Brands, Breg Inc., Medline Industries LP, Performance Health Supply Inc., Romsons Group of Industries, Beiersdorf AG, DJO Global Inc., Gilead Sciences Inc., Astellas Pharma Inc., AstraZeneca PLC, Novo Nordisk A/S, Polar Products Inc., The Bristol-Myers Squibb Company, Mueller Sports Medicine Inc., Eli Lilly and Company, Bruder Healthcare Company LLC, ThermoTek Inc., Boehringer Ingelheim International GmbH, GlaxoSmithKline PLC, Medtronic PLC, Performance Health LLC.

North America was the largest region in the cold pain therapy market share in 2024. The regions covered in the cold pain therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cold pain therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Cold pain therapy refers to a treatment method used to effectively reduce inflammation and swelling, primarily aiming to alleviate pain. The key objective is to address injuries causing pain by lowering the temperature at the surface of the affected area.

The main products in cold pain therapy include over-the-counter (OTC) and prescription products. OTC cold pain therapy products are designed to efficiently reduce inflammation and swelling by lowering the temperature around the pain area. These products can be purchased without a prescription and are distributed through various channels such as retail pharmacies, hospital pharmacies, and e-pharmacies. They are commonly used for the treatment of musculoskeletal disorders, post-operative therapy, sports injuries, and post-trauma therapy.

The cold pain therapy market research report is one of a series of new reports that provides cold pain therapy market statistics, including cold pain therapy industry global market size, regional shares, competitors with a cold pain therapy market share, detailed cold pain therapy market segments, market trends and opportunities, and any further data you may need to thrive in the cold pain therapy industry. This cold pain therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cold pain therapy market consists of sales of gels, ointments, creams, and foams. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.